SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (746)3/20/2007 12:33:18 PM
From: keokalani'nui  Respond to of 824
 
Just one moderate president away from changing orphan drug economics....



To: Robohogs who wrote (746)3/20/2007 1:02:34 PM
From: rkrw  Read Replies (1) | Respond to of 824
 
Pricing is outrageous. And supposedly mfg costs have come way down in general, so can't blame it all on that.

The basic pricing equation is to work backward, how big do you want a drug to be divided by number of patients. $500M seems to be the bare minimum starting point. alxn will price as high as they can get away with.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News